Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
PharmaCielo Ltd. (TSXV:PCLO) (OTC:PCLOF) announced its financial results on Thursday for the fourth quarter and year ended December 31, 2023, as well as for the first quarter ended March 31, 2024.
The Canadian parent of Colombia’s cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., also said that effective as of July 3, 2024, its principal regulator, the Ontario Securities Commission has revoked its failure to file a cease trade order that was issued on May 7, 2024, due to the delay in filing its audited annual consolidated financial statements for the year ended December 31, 2023.
“Our team has been unwavering in their efforts to drastically reduce costs and optimize operations while expanding our sales reach," said Marc Lustig, chairman and CEO of PharmaCielo. "The global landscape for cannabinoid-based drugs and therapeutics is expanding, and we are strategically positioned to seize opportunities in regions such as Latin America, Australia, and Europe."
PharmaCielo reported the TSX Venture Exchange has changed its tier classification from tier 1 to tier 2, effective June 20, 2024, as the company does not meet the exchange’s tier 1 continued listing requirements.
Now Read:
To learn more about cannabis stocks, come, join us at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.